1. Role: Director. Scope: Department. Date: 2019.
Grant H. Skrepnek, Ph.D., R.Ph.
Professor
Pharmacy Clinical & Admin Sci
Phone (405) 271-6878 x47105
Fax (4050 271-6430
Office CPB 214
Email grant-skrepnek@ouhsc.edu
Summary
I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Research
Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Publications & Presentations
- 111. Skrepnek G H, Armstrong E P, Malone D C, Ramachandran S. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care. Current medical research and opinion. 2005; 21 : 261-70
112. Skrepnek G H, Skrepnek S V. An assessment of therapeutic regimens in the treatment of acute exacerbations in chronic obstructive pulmonary disease and asthma. The American journal of managed care. 2004; 10 : S139-52
113. Skrepnek G H, Skrepnek S V. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. The American journal of managed care. 2004; 10 : S129-38
114. Skrepnek G H. Accounting- versus economic-based rates of return: implications for profitability measures in the pharmaceutical industry. Clinical therapeutics. 2004; 26 : 155-74
115. Lai L K, Armstrong E P, Salcido A L, French R, Skrepnek G H. Women's perception of bone-mineral density testing and osteoporosis education in the community pharmacy. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2003; 18 : 968-76
Grants
- 11. Improving the Health of Americans through Prevention and Management of Diabetes, Heart Disease, and Stroke. Non-federal. Start Date: 2019. End Date: 2020.
12. Allergan (PI: Keast). Federal Non-NIH. Start Date: 2018. End Date: 2019.
13. Otsuka (Skrepnek/Keast PI). Non-federal. Start Date: 2018. End Date: 2019.
14. Research Fellowship. PhRMA. Start Date: 2017. End Date: 2018.
15. Development of a Predictive Model for METAVIR Fibrosis Scores for Patients Chronically Infected with Hepatitis C Virus. Misc Non-Federal. Start Date: 2017.
Awards and Honors
no results
Education
no results
Administrative Assignments
2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.